Date: Sunday, November 5, 2017
Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: Obesity is a risk factor for the development and severity of psoriatic arthritis (PsA).1,2 Patients (pts) with increased BMI (overweight/obese) are less likely to achieve sustained minimal disease activity (MDA) vs those with normal BMI, independent of biologic and non-biologic DMARD use.3 Moreover, obese pts with PsA respond less favourably to TNFα inhibitors vs normal BMI pts.4,5 In the Phase III ASTRAEA study (NCT01860976),6 abatacept (ABA) significantly improved disease activity and was well tolerated; the primary endpoint of ACR20 at 24 weeks (W) was met.6 We evaluated the relationship beween BMI and ABA response in a post hoc analysis of ASTRAEA.
Results: Overall, 212 ABA- and 210 PBO-treated pts had available baseline BMI status. For ABA vs PBO, respectively, 31 (14.6%) vs 39 (18.6%) were underweight/normal, 77 (36.3%) vs 57 (27.1%) were overweight and 104 (49.1%) vs 114 (54.3%) were obese. In the ABA and PBO groups, neither overweight nor obese pts had a significantly lower ACR20 response vs underweight/normal pts in the univariate model. This was confirmed in the multivariate models in overweight and obese pts, respectively, vs underweight/normal pts: ABA: OR (95% CI) 1.215 (0.437, 3.378), p=0.7087 and 0.446 (0.162, 1.228), p=0.1181; PBO: OR (95% CI) 0.554 (0.189, 1.621), p=0.2811 and 0.460 (0.166, 1.271), p=0.1343. Similar results were observed for all other outcomes tested (Figure).
1. Kumar S, et al. J Eur Acad Dermatol Venereol 2013;27:1293–8.
2. Armstrong AW, et al. Nutr Diabetes 2012;2:e54.
3. Eder L, et al. Ann Rheum Dis 2015;74:813–7.
4. di Minno MN, et al. Arthritis Care Res (Hoboken) 2013;65:141–7.
5. Gremese E, et al. Front Immunol 2014;5:576.
To cite this abstract in AMA style:McInnes IB, Ferraccioli G, D'Agostino M, Le Bars M, Banerjee S, Ahmad H, Elbez Y, Ye J, Mease PJ. Body Mass Index Does Not Influence the Efficacy of Subcutaneous Abatacept in Patients with Psa: Results from a Phase III Trial [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/body-mass-index-does-not-influence-the-efficacy-of-subcutaneous-abatacept-in-patients-with-psa-results-from-a-phase-iii-trial/. Accessed September 18, 2021.
« Back to 2017 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/body-mass-index-does-not-influence-the-efficacy-of-subcutaneous-abatacept-in-patients-with-psa-results-from-a-phase-iii-trial/